Virax Biolabs Group Ltd 6-K Filing
Ticker: VRAX · Form: 6-K · Filed: Dec 2, 2025 · CIK: 1885827
| Field | Detail |
|---|---|
| Company | Virax Biolabs Group Ltd (VRAX) |
| Form Type | 6-K |
| Filed Date | Dec 2, 2025 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Virax Biolabs Group Ltd (ticker: VRAX) to the SEC on Dec 2, 2025.
How long is this filing?
Virax Biolabs Group Ltd's 6-K filing is 1 pages with approximately 282 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 282 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2025-12-02 16:42:09
Filing Documents
- 6-k_fy2026_q2_results.htm (6-K) — 30KB
- vrax-ex99_1.htm (EX-99.1) — 1350KB
- vrax-ex99_2.htm (EX-99.2) — 217KB
- 0001193125-25-305371.txt ( ) — 1598KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIRAX BIOLABS GROUP LIMITED Date: December 2, 2025 By: /s/ James Foster James Foster, Chief Executive Officer